Brief communication: efficacy and safety of the dolutegravir/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIV
Abstract This study aimed to evaluate the efficacy and safety of dolutegravir plus lamivudine (DTG/3TC) in antiretroviral treatment (ART)-experienced people living with HIV (PLWH). A total of 303 PLWH in Shanghai, China, who switched from triple ART to DTG/3TC between January 2019 and June 2022, wit...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | AIDS Research and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12981-024-00680-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846147461131796480 |
|---|---|
| author | Zhenyan Wang Junyang Yang Lin Wang Jiangrong Wang Yinzhong Shen Jun Chen Tangkai Qi Jianjun Sun Wei Song Yang Tang Shuibao Xu Li Liu Renfang Zhang |
| author_facet | Zhenyan Wang Junyang Yang Lin Wang Jiangrong Wang Yinzhong Shen Jun Chen Tangkai Qi Jianjun Sun Wei Song Yang Tang Shuibao Xu Li Liu Renfang Zhang |
| author_sort | Zhenyan Wang |
| collection | DOAJ |
| description | Abstract This study aimed to evaluate the efficacy and safety of dolutegravir plus lamivudine (DTG/3TC) in antiretroviral treatment (ART)-experienced people living with HIV (PLWH). A total of 303 PLWH in Shanghai, China, who switched from triple ART to DTG/3TC between January 2019 and June 2022, with a minimum ART duration of 6 months, were retrospectively enrolled. More than 95% of PLWH maintained viral suppression with no significant changes in CD4 counts 12 months after switching. Patients transitioning from non-tenofovir (TDF)-based regimens demonstrated more pronounced improvements in lipid profiles, while those previously on TDF-based regimens showed greater enhancements in bone metabolism. |
| format | Article |
| id | doaj-art-fd4c28b7fa794a2ab3a07751ab1c31b2 |
| institution | Kabale University |
| issn | 1742-6405 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMC |
| record_format | Article |
| series | AIDS Research and Therapy |
| spelling | doaj-art-fd4c28b7fa794a2ab3a07751ab1c31b22024-12-01T12:45:54ZengBMCAIDS Research and Therapy1742-64052024-11-012111510.1186/s12981-024-00680-xBrief communication: efficacy and safety of the dolutegravir/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIVZhenyan Wang0Junyang Yang1Lin Wang2Jiangrong Wang3Yinzhong Shen4Jun Chen5Tangkai Qi6Jianjun Sun7Wei Song8Yang Tang9Shuibao Xu10Li Liu11Renfang Zhang12Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan UniversityDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan UniversityDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan UniversityDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan UniversityDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan UniversityDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan UniversityDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan UniversityDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan UniversityDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan UniversityDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan UniversityDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan UniversityDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan UniversityDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan UniversityAbstract This study aimed to evaluate the efficacy and safety of dolutegravir plus lamivudine (DTG/3TC) in antiretroviral treatment (ART)-experienced people living with HIV (PLWH). A total of 303 PLWH in Shanghai, China, who switched from triple ART to DTG/3TC between January 2019 and June 2022, with a minimum ART duration of 6 months, were retrospectively enrolled. More than 95% of PLWH maintained viral suppression with no significant changes in CD4 counts 12 months after switching. Patients transitioning from non-tenofovir (TDF)-based regimens demonstrated more pronounced improvements in lipid profiles, while those previously on TDF-based regimens showed greater enhancements in bone metabolism.https://doi.org/10.1186/s12981-024-00680-xHIVDolutegravirLamivudineAntiretroviral |
| spellingShingle | Zhenyan Wang Junyang Yang Lin Wang Jiangrong Wang Yinzhong Shen Jun Chen Tangkai Qi Jianjun Sun Wei Song Yang Tang Shuibao Xu Li Liu Renfang Zhang Brief communication: efficacy and safety of the dolutegravir/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIV AIDS Research and Therapy HIV Dolutegravir Lamivudine Antiretroviral |
| title | Brief communication: efficacy and safety of the dolutegravir/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIV |
| title_full | Brief communication: efficacy and safety of the dolutegravir/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIV |
| title_fullStr | Brief communication: efficacy and safety of the dolutegravir/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIV |
| title_full_unstemmed | Brief communication: efficacy and safety of the dolutegravir/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIV |
| title_short | Brief communication: efficacy and safety of the dolutegravir/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIV |
| title_sort | brief communication efficacy and safety of the dolutegravir lamivudine dual therapy in antiretroviral treatment experienced chinese people living with hiv |
| topic | HIV Dolutegravir Lamivudine Antiretroviral |
| url | https://doi.org/10.1186/s12981-024-00680-x |
| work_keys_str_mv | AT zhenyanwang briefcommunicationefficacyandsafetyofthedolutegravirlamivudinedualtherapyinantiretroviraltreatmentexperiencedchinesepeoplelivingwithhiv AT junyangyang briefcommunicationefficacyandsafetyofthedolutegravirlamivudinedualtherapyinantiretroviraltreatmentexperiencedchinesepeoplelivingwithhiv AT linwang briefcommunicationefficacyandsafetyofthedolutegravirlamivudinedualtherapyinantiretroviraltreatmentexperiencedchinesepeoplelivingwithhiv AT jiangrongwang briefcommunicationefficacyandsafetyofthedolutegravirlamivudinedualtherapyinantiretroviraltreatmentexperiencedchinesepeoplelivingwithhiv AT yinzhongshen briefcommunicationefficacyandsafetyofthedolutegravirlamivudinedualtherapyinantiretroviraltreatmentexperiencedchinesepeoplelivingwithhiv AT junchen briefcommunicationefficacyandsafetyofthedolutegravirlamivudinedualtherapyinantiretroviraltreatmentexperiencedchinesepeoplelivingwithhiv AT tangkaiqi briefcommunicationefficacyandsafetyofthedolutegravirlamivudinedualtherapyinantiretroviraltreatmentexperiencedchinesepeoplelivingwithhiv AT jianjunsun briefcommunicationefficacyandsafetyofthedolutegravirlamivudinedualtherapyinantiretroviraltreatmentexperiencedchinesepeoplelivingwithhiv AT weisong briefcommunicationefficacyandsafetyofthedolutegravirlamivudinedualtherapyinantiretroviraltreatmentexperiencedchinesepeoplelivingwithhiv AT yangtang briefcommunicationefficacyandsafetyofthedolutegravirlamivudinedualtherapyinantiretroviraltreatmentexperiencedchinesepeoplelivingwithhiv AT shuibaoxu briefcommunicationefficacyandsafetyofthedolutegravirlamivudinedualtherapyinantiretroviraltreatmentexperiencedchinesepeoplelivingwithhiv AT liliu briefcommunicationefficacyandsafetyofthedolutegravirlamivudinedualtherapyinantiretroviraltreatmentexperiencedchinesepeoplelivingwithhiv AT renfangzhang briefcommunicationefficacyandsafetyofthedolutegravirlamivudinedualtherapyinantiretroviraltreatmentexperiencedchinesepeoplelivingwithhiv |